GlobeNewswire

Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results
06/11/2026
EDEN PRAIRIE, Minn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live [...]
Entera Announces Third Quarter 2026 Financial Results and Business Updates
06/11/2026
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Executives and Directors EB613 [...]
Amwell makes grant to new employees under inducement plan
06/11/2026
BOSTON, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, announces that on November 6, Amwell made grants of [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
MALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026
06/11/2026
Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET PORTLAND, Maine, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics [...]
Spyre Therapeutics Announces Grants of Inducement Awards
06/11/2026
WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
LeMaitre to Participate in Upcoming Investor Conferences
06/11/2026
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Stifel 2026 Healthcare Conference [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
National Tirzepatide Online Telehealth Provider Ozari Health Launches Ozari Select Monthly Plan in All 50 States
06/11/2026
Ozari Select gives patients in every state, including California, month-to-month access to compounded tirzepatide at $235 and compounded semaglutide at $175, with a choice of three formulations, two named US-licensed [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
06/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
06/11/2026
HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks Data support a [...]
Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement
06/11/2026
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic [...]
Ipsen - October 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
06/11/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Octobre 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/11/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum